Gene Polymorphisms in Boar Spermatozoa and Their Associations with Post-Thaw Semen Quality
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
OXSR1 (A-4): Sc-271707
SANTA CRUZ BIOTECHNOLOGY, INC. OXSR1 (A-4): sc-271707 BACKGROUND APPLICATIONS Oxidative stress-responsive 1 protein (OXSR1), a protein of 527 amino acids, OXSR1 (A-4) is recommended for detection of OXSR1 of mouse, rat and belongs to the STE20 subfamily. OXSR1 is one of two human homologs of human origin by Western Blotting (starting dilution 1:100, dilution range Fray, a serine/threonine kinase expressed in Drosophila. OXSR1 binds to and 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein phosphorylates p21-activated protein kinase (PAK1) and regulates downstream (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution kinases in response to environmental stress. Endogenous OXSR1 is activated range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution only by osmotic stresses, notably sorbitol and to a lesser extent NaCl. OXSR1 range 1:30-1:3000). may also play a role in regulating the Actin cytoskeleton. The chloride channel Suitable for use as control antibody for OXSR1 siRNA (h): sc-61273, OXSR1 proteins SLC12A1, SLC12A2 and SLC12A6 isoform 2 interact with OXSR1, siRNA (m): sc-61274, OXSR1 shRNA Plasmid (h): sc-61273-SH, OXSR1 but SLC12A4 and SLC12A7 do not. The WNK1 and WNK4 protein kinases shRNA Plasmid (m): sc-61274-SH, OXSR1 shRNA (h) Lentiviral Particles: activate OXSR1 by phosphorlating its T-loop. The OXSR1 protein is widely sc-61273-V and OXSR1 shRNA (m) Lentiviral Particles: sc-61274-V. expressed in mammalian tissues. Molecular Weight of OXSR1: 58 kDa. REFERENCES Positive Controls: OXSR1 (h3): 293 Lysate: sc-158793, HeLa whole cell lysate: 1. -
The Role of PARP1 in Monocyte and Macrophage
cells Review The Role of PARP1 in Monocyte and Macrophage Commitment and Specification: Future Perspectives and Limitations for the Treatment of Monocyte and Macrophage Relevant Diseases with PARP Inhibitors Maciej Sobczak 1, Marharyta Zyma 2 and Agnieszka Robaszkiewicz 1,* 1 Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland; [email protected] 2 Department of Immunopathology, Medical University of Lodz, 7/9 Zeligowskiego, Bldg 2, Rm177, 90-752 Lodz, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-42-6354449; Fax: +48-42-6354449 or +48-42-635-4473 Received: 4 August 2020; Accepted: 4 September 2020; Published: 6 September 2020 Abstract: Modulation of PARP1 expression, changes in its enzymatic activity, post-translational modifications, and inflammasome-dependent cleavage play an important role in the development of monocytes and numerous subtypes of highly specialized macrophages. Transcription of PARP1 is governed by the proliferation status of cells at each step of their development. Higher abundance of PARP1 in embryonic stem cells and in hematopoietic precursors supports their self-renewal and pluri-/multipotency, whereas a low level of the enzyme in monocytes determines the pattern of surface receptors and signal transducers that are functionally linked to the NFκB pathway. In macrophages, the involvement of PARP1 in regulation of transcription, signaling, inflammasome activity, metabolism, and redox balance supports macrophage polarization towards the pro-inflammatory phenotype (M1), which drives host defense against pathogens. On the other hand, it seems to limit the development of a variety of subsets of anti-inflammatory myeloid effectors (M2), which help to remove tissue debris and achieve healing. -
(MMP-9) in Oral Cancer Squamous Cells—Are There Therapeutical Hopes?
materials Article Lutein Treatment Effects on the Redox Status and Metalloproteinase-9 (MMP-9) in Oral Cancer Squamous Cells—Are There Therapeutical Hopes? 1 2,3 4 1 Dan Alexandru Enăs, escu , Mihaela Georgeta Moisescu , Marina Imre , Maria Greabu , Alexandra Ripszky Totan 1,* , Iulia Stanescu-Spinu 1, Marian Burcea 5, Crenguta Albu 6,* and Daniela Miricescu 1 1 Department of Biochemistry, Faculty of Dental Medicine, University of Medicine and Pharmacy Carol Davila, 8 Eroii Sanitari Blvd., Sector 5, 050474 Bucharest, Romania; [email protected] (D.A.E.); [email protected] (M.G.); [email protected] (I.S.-S.); [email protected] (D.M.) 2 Department Biophysics and Cellular Biotechnology, University of Medicine and Pharmacy Carol Davila, 8 Eroii Sanitari Blvd., Sector 5, 050474 Bucharest, Romania; [email protected] 3 Excellence Centre for Research in Biophysics and Cellular Biotechnology, University of Medicine and Pharmacy Carol Davila, 8 Eroii Sanitari Blvd., Sector 5, 050474 Bucharest, Romania 4 Department of Complete Denture, Faculty of Dental Medicine, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Blvd., Sector 5, 050474 Bucharest, Romania; [email protected] 5 Department of Ophthalmology, Faculty of General Medicine, University of Medicine and Pharmacy Carol Davila, 8 Eroilor Sanitari Blvd., 050474 Bucharest, Romania; [email protected] 6 Department of Genetics, Faculty of General Medicine, University of Medicine and Pharmacy Carol Davila, 8 Eroilor Sanitari Blvd., 050474 Bucharest, Romania * Correspondence: [email protected] (A.R.T.); [email protected] (C.A.) Citation: En˘as, escu, D.A.; Moisescu, M.G.; Imre, M.; Greabu, M.; Ripszky Totan, A.; Stanescu-Spinu, I.; Burcea, Abstract: Carotenoids loaded in nanoparticles should be regarded as a promising way to increase M.; Albu, C.; Miricescu, D. -
A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated. -
OXSR1 Mouse Monoclonal Antibody [Clone ID: OTI1F3] Product Data
OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA500392 OXSR1 Mouse Monoclonal Antibody [Clone ID: OTI1F3] Product data: Product Type: Primary Antibodies Clone Name: OTI1F3 Applications: IHC, WB Recommended Dilution: WB 1:1000, IHC 1:150 Reactivity: Human, Monkey, Mouse, Rat, Dog Host: Mouse Isotype: IgG1 Clonality: Monoclonal Immunogen: Full-length protein expressed in 293T cell transfected with human OXSR1 expression vector Formulation: PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide. Concentration: 1.28 mg/ml Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G) Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 57.8 kDa Gene Name: oxidative stress responsive kinase 1 Database Link: NP_005100 Entrez Gene 108737 MouseEntrez Gene 316064 RatEntrez Gene 607809 DogEntrez Gene 696362 MonkeyEntrez Gene 9943 Human O95747 Background: The product of this gene belongs to the Ser/Thr protein kinase family of proteins. It regulates downstream kinases in response to environmental stress, and may play a role in regulating the actin cytoskeleton.Regulates downstream kinases in response to environmental stress. May also have a function in regulating the actin cytoskeleton Synonyms: OSR1 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 OXSR1 Mouse Monoclonal Antibody [Clone ID: OTI1F3] – TA500392 Protein Families: Druggable Genome, Protein Kinase Product images: HEK293T cells were transfected with the pCMV6- ENTRY control (Cat# [PS100001], Left lane) or pCMV6-ENTRY OXSR1 (Cat# [RC200396], Right lane) cDNA for 48 hrs and lysed. -
Noninvasive Sleep Monitoring in Large-Scale Screening of Knock-Out Mice
bioRxiv preprint doi: https://doi.org/10.1101/517680; this version posted January 11, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Noninvasive sleep monitoring in large-scale screening of knock-out mice reveals novel sleep-related genes Shreyas S. Joshi1*, Mansi Sethi1*, Martin Striz1, Neil Cole2, James M. Denegre2, Jennifer Ryan2, Michael E. Lhamon3, Anuj Agarwal3, Steve Murray2, Robert E. Braun2, David W. Fardo4, Vivek Kumar2, Kevin D. Donohue3,5, Sridhar Sunderam6, Elissa J. Chesler2, Karen L. Svenson2, Bruce F. O'Hara1,3 1Dept. of Biology, University of Kentucky, Lexington, KY 40506, USA, 2The Jackson Laboratory, Bar Harbor, ME 04609, USA, 3Signal solutions, LLC, Lexington, KY 40503, USA, 4Dept. of Biostatistics, University of Kentucky, Lexington, KY 40536, USA, 5Dept. of Electrical and Computer Engineering, University of Kentucky, Lexington, KY 40506, USA. 6Dept. of Biomedical Engineering, University of Kentucky, Lexington, KY 40506, USA. *These authors contributed equally Address for correspondence and proofs: Shreyas S. Joshi, Ph.D. Dept. of Biology University of Kentucky 675 Rose Street 101 Morgan Building Lexington, KY 40506 U.S.A. Phone: (859) 257-2805 FAX: (859) 257-1717 Email: [email protected] Running title: Sleep changes in knockout mice bioRxiv preprint doi: https://doi.org/10.1101/517680; this version posted January 11, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. -
OSR1 (Phospho Thr185) Antibody Cat
OSR1 (phospho Thr185) Antibody Cat. No.: 79-859 OSR1 (phospho Thr185) Antibody Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using OSR1 (Phospho-Thr185) antibody (left) or the same antibody preincubated with blocking peptide (right). Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Human, Mouse OSR1 (phospho Thr185) antibody was raised against a peptide sequence around IMMUNOGEN: phosphorylation site of threonine185 (R-K-T (p)-F-V) derived from Human OSR1. TESTED APPLICATIONS: IHC, WB APPLICATIONS: Western Blot: 1:500~1:1000, Immunohistochemistry: 1:50~1:100 The antibody detects endogenous levels of OSR1 only when phosphorylated at threonine SPECIFICITY: 185. PREDICTED MOLECULAR 65 kDa WEIGHT: September 29, 2021 1 https://www.prosci-inc.com/osr1-phospho-thr185-antibody-79-859.html Properties PURIFICATION: Antibodies were purified by affinity-chromatography using epitope-specific peptide. CLONALITY: Polyclonal ISOTYPE: IgG CONJUGATE: Unconjugated PHYSICAL STATE: Liquid Antibody supplied in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM BUFFER: NaCl, 0.02% sodium azide and 50% glycerol. CONCENTRATION: 1 mg/mL STORAGE CONDITIONS: Store antibody at -20˚C for up to one year. Additional Info OFFICIAL SYMBOL: OXSR1 ALTERNATE NAMES: OXSR1, kinase OSR1, Oxidative-stress responsive 1 ACCESSION NO.: NP_005100.1 PROTEIN GI NO.: 4826878 GENE ID: 9943 Background and References Oxidative-stress responsive 1 gene is located in the vicinity of three others genes - GOLGA4, ITGA9 and HYA22 on chromosome 3. These four genes are considered to be BACKGROUND: candidate tumor suppressors. Oxidative-stress responsive 1 protein has similarity to human Ste20/oxidant stress response kinase-1 and is thought to be involved in the response to oxidative stress REFERENCES: 1) Tamari M., J. -
Human OXSR1 / OSR1 (1-527, His-Tag) - Purified
OriGene Technologies, Inc. OriGene Technologies GmbH 9620 Medical Center Drive, Ste 200 Schillerstr. 5 Rockville, MD 20850 32052 Herford UNITED STATES GERMANY Phone: +1-888-267-4436 Phone: +49-5221-34606-0 Fax: +1-301-340-8606 Fax: +49-5221-34606-11 [email protected] [email protected] AR51668PU-N Human OXSR1 / OSR1 (1-527, His-tag) - Purified Alternate names: KIAA1101, Oxidative stress-responsive 1 protein, Serine/threonine-protein kinase OSR1 Quantity: 0.5 mg Concentration: 0.5 mg/ml (determined by Bradford assay) Background: OXSR1 is a member of the neuronal calcium sensor gene family, which encode calcium-binding proteins expressed predominantly in neurons. This protein regulates G protein-coupled receptor phosphorylation in a calcium-dependent manner and can substitute for calmodulin. It is associated with secretory granules and modulates synaptic transmission and synaptic plasticity. Multiple transcript variants encoding different isoforms have been found for this gene. Uniprot ID: O95747 NCBI: NP_005100 GeneID: 9943 Species: Human Source: E. coli Format: State: Liquid purified protein Purity: >85% by SDS - PAGE Buffer System: 1 X Phosphate Buffered Saline (pH7.4) containing 30% glycerol, 1mM DTT. Description: Recombinant human OXSR1 protein, fused to His-tag at N-terminus, was expressed in E.coli and purified by using conventional chromatography techniques. AA Sequence: MGSSHHHHHH SSGLVPRGSH MGSMSEDSSA LPWSINRDDY ELQEVIGSGA TAVVQAAYCA PKKEKVAIKR INLEKCQTSM DELLKEIQAM SQCHHPNIVS YYTSFVVKDE LWLVMKLLSG GSVLDIIKHI VAKGEHKSGV LDESTIATIL REVLEGLEYL HKNGQIHRDV KAGNILLGED GSVQIADFGV SAFLATGGDI TRNKVRKTFV GTPCWMAPEV MEQVRGYDFK ADIWSFGITA IELATGAAPY HKYPPMKVLM LTLQNDPPSL ETGVQDKEML KKYGKSFRKM ISLCLQKDPE KRPTAAELLR HKFFQKAKNK EFLQEKTLQR APTISERAKK VRRVPGSSGR LHKTEDGGWE WSDDEFDEES EEGKAAISQL RSPRVKESIS NSELFPTTDP VGTLLQVPEQ ISAHLPQPAG QIATQPTQVS LPPTAEPAKT AQALSSGSGS QETKIPISLV LRLRNSKKEL NDIRFEFTPG RDTAEGVSQE LISAGLVDGR DLVIVAANLQ KIVEEPQSNR SVTFKLASGV EGSDIPDDGK LIGFAQLSIS Molecular weight: 60.4. -
Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase -
Identification of Candidate Genes and Pathways Associated with Obesity
animals Article Identification of Candidate Genes and Pathways Associated with Obesity-Related Traits in Canines via Gene-Set Enrichment and Pathway-Based GWAS Analysis Sunirmal Sheet y, Srikanth Krishnamoorthy y , Jihye Cha, Soyoung Choi and Bong-Hwan Choi * Animal Genome & Bioinformatics, National Institute of Animal Science, RDA, Wanju 55365, Korea; [email protected] (S.S.); [email protected] (S.K.); [email protected] (J.C.); [email protected] (S.C.) * Correspondence: [email protected]; Tel.: +82-10-8143-5164 These authors contributed equally. y Received: 10 October 2020; Accepted: 6 November 2020; Published: 9 November 2020 Simple Summary: Obesity is a serious health issue and is increasing at an alarming rate in several dog breeds, but there is limited information on the genetic mechanism underlying it. Moreover, there have been very few reports on genetic markers associated with canine obesity. These studies were limited to the use of a single breed in the association study. In this study, we have performed a GWAS and supplemented it with gene-set enrichment and pathway-based analyses to identify causative loci and genes associated with canine obesity in 18 different dog breeds. From the GWAS, the significant markers associated with obesity-related traits including body weight (CACNA1B, C22orf39, U6, MYH14, PTPN2, SEH1L) and blood sugar (PRSS55, GRIK2), were identified. Furthermore, the gene-set enrichment and pathway-based analysis (GESA) highlighted five enriched pathways (Wnt signaling pathway, adherens junction, pathways in cancer, axon guidance, and insulin secretion) and seven GO terms (fat cell differentiation, calcium ion binding, cytoplasm, nucleus, phospholipid transport, central nervous system development, and cell surface) which were found to be shared among all the traits. -
(12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown Et Al
US 20030082511A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown et al. (43) Pub. Date: May 1, 2003 (54) IDENTIFICATION OF MODULATORY Publication Classification MOLECULES USING INDUCIBLE PROMOTERS (51) Int. Cl." ............................... C12O 1/00; C12O 1/68 (52) U.S. Cl. ..................................................... 435/4; 435/6 (76) Inventors: Steven J. Brown, San Diego, CA (US); Damien J. Dunnington, San Diego, CA (US); Imran Clark, San Diego, CA (57) ABSTRACT (US) Correspondence Address: Methods for identifying an ion channel modulator, a target David B. Waller & Associates membrane receptor modulator molecule, and other modula 5677 Oberlin Drive tory molecules are disclosed, as well as cells and vectors for Suit 214 use in those methods. A polynucleotide encoding target is San Diego, CA 92121 (US) provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the (21) Appl. No.: 09/965,201 cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a (22) Filed: Sep. 25, 2001 result of the candidate modulatory molecule. Patent Application Publication May 1, 2003 Sheet 1 of 8 US 2003/0082511 A1 KCNC1 cDNA F.G. 1 Patent Application Publication May 1, 2003 Sheet 2 of 8 US 2003/0082511 A1 49 - -9 G C EH H EH N t R M h so as se W M M MP N FIG.2 Patent Application Publication May 1, 2003 Sheet 3 of 8 US 2003/0082511 A1 FG. 3 Patent Application Publication May 1, 2003 Sheet 4 of 8 US 2003/0082511 A1 KCNC1 ITREXCHO KC 150 mM KC 2000000 so 100 mM induced Uninduced Steady state O 100 200 300 400 500 600 700 Time (seconds) FIG. -
Grant Application Form Please Complete the Following Form for IETF
©2007 IETF Grant Application Form Please complete the following form for IETF grant applications. This form and all the attachments below must be combined into one document before submitting electronically. Grant submissions will not be accepted otherwise. Attachments Required 1. Specific aims of the proposal (1 page maximum). 2. Rationale of the proposal and relevance to essential tremor (1-2 pages maximum). 3. Preliminary data, if available should be incorporated into the Rationale/Relevance section. Preliminary data are not required for a proposal. However, if preliminary data are referred to in the proposal rationale, or have been used to formulate the hypotheses to be tested, such information must be formally presented in this section. 4. Research methods and procedures (1-2 pages maximum). 5. Anticipated results (half-page maximum). 6. Detailed budget and justification (1 page maximum). 7. Biographic sketch of principal investigator and all professional personnel participating in the project (standard NIH format, including biosketch and other support). 8. Copies of relevant abstracts and/or articles that have been published, are in press, or have been submitted for publication. 9. Completed conflict of interest questionnaire. Project Title: ____________________________________________________________________________ Sponsoring Institution: ____________________________________________________________________ Principal Investigator: Last Name: _______________________________ First Name: ______________________ Middle Initial: __ Degree(s):